CD19 and lymphoma: Indeed, recent data showed that the simultaneous administration of selinexor with CAR-T cell therapy was not beneficial in lymphoma models [57], however the sequential administration of selinexor and then CD19 targeted CAR-T cells provided enhanced efficacy compared to selinexor or CAR-T cells alone [58].